Cargando…
Angiotensin‐converting enzyme inhibitors increase anti‐fibrotic biomarkers in African Americans with left ventricular hypertrophy
Angiotensin‐converting enzyme inhibitors (ACEi) are part of the indicated treatment in hypertensive African Americans. ACEi have blood pressure‐independent effects that may make them preferred for certain patients. We aimed to evaluate the impact of ACEi on anti‐fibrotic biomarkers in African Americ...
Autores principales: | A. Romero, Cesar, Mathew, Shobi, Wasinski, Benjamin, Reed, Brian, Brody, Aaron, Dawood, Rachelle, Twiner, Michael J., McNaughton, Candace D., Fridman, Rafael, Flack, John M., Carretero, Oscar A., Levy, Phillip D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8678784/ https://www.ncbi.nlm.nih.gov/pubmed/33694311 http://dx.doi.org/10.1111/jch.14206 |
Ejemplares similares
-
The significance of plasma collagen degradation products as biomarkers for advanced hypertensive heart disease
por: Mani, Kevin, et al.
Publicado: (2021) -
Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin–angiotensin–aldosterone system in patients with heart failure
por: Boorsma, Eva M., et al.
Publicado: (2021) -
Giving anti-VEGF injections: an update from Burundi
por: Niyonzima, Jean Claude
Publicado: (2023) -
The Its Not JUST Idiopathic pulmonary fibrosis Study (INJUSTIS): description of the protocol for a multicentre prospective observational cohort study identifying biomarkers of progressive fibrotic lung disease
por: Khan, Fasihul, et al.
Publicado: (2019) -
The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines
por: Wei, Jiao, et al.
Publicado: (2022)